Pharmacokinetics and toxicity of two schedules of high dose epirubicin

• Published in: Cancer research (Chicago, Ill.) Vol. 50; no. 16; pp. 5095 - 5101
• Main Authors: TJULJANDIN, S. A, DOIG, R. G, SOBOL, M. M, MCGREGOR WASTON, D, SHERIDAN, W. P, MORSTYN, G, MIHALY, G, GREEN, M. D
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15-08-1990
• Subjects: Antineoplastic agents; Biological and medical sciences; Biotransformation; Chemotherapy; Chromatography, High Pressure Liquid; Drug Administration Schedule; Epirubicin - adverse effects; Epirubicin - pharmacokinetics; Epirubicin - therapeutic use; Female; Humans; Injections, Intravenous; Leukocyte Count - drug effects; Male; Medical sciences; Middle Aged; Neoplasms - drug therapy; Pharmacology. Drug treatments; Platelet Count - drug effects; Antineoplastic agent; Human; Intravenous administration; Toxicity; Advanced stage; Anthracyclins; Malignant tumor; Pharmacokinetics; High dose
• ISSN: 0008-5472; 1538-7445

Epirubicin, a stereoisomer of doxorubicin, is reported to have equal antitumor activity with lower cardiac and systemic toxicity. Recently the maximum tolerated dose of this drug has been revised upwards with reported increased response rates. However, the pharmacokinetics of epirubicin at high doses have never been reported. Accordingly, this study was designed to evaluate the pharmacokinetics of epirubicin when administered as either a 15-min i.v. bolus or a 6-h i.v. infusion in a phase I study at high doses. Nineteen patients with a variety of malignancies were given a total of 52 cycles of epirubicin at doses of 90 to 150 mg/m2 given once every 3 weeks. The maximum tolerated dose was 150 mg/m2 epirubicin given either as a bolus or as an infusion. The major dose-limiting toxicity was neutropenia. Interpatient variation occurred in the pharmacokinetics at each dose level but overall there were dose-dependent pharmacokinetics. This was manifested as a disproportionate increase in plasma levels and areas under the curve as the epirubicin dose was increased from 90 to 150 mg/m2. The pharmacokinetics of epirubicin could best be described by an open two-compartment model. Peak plasma concentrations were attained at a median of 12 min following the bolus injection and concentrations approached the steady state within a median of 55 min following the start of the 6-h infusion. Administration of the 150 mg/m2 dose over the 6 h compared to the bolus administration was associated with a 92% decrease in peak concentration from 3088 +/- 1503 to 234 +/- 126 ng/ml. This was not associated with an appreciable change in hematological or nonhematological toxicities. The median distribution half-life was 10 min and the median elimination half-life was 42.0 h. The cumulative renal excretion of the parent compound accounted for less than 2% of the administered dose. The major metabolites in both plasma and urine samples were 4'-O-beta-D-glucuronyl-4'-epidoxorubicin, 13-S-dihydro-4'-epidoxorubicin, and 4'-O-beta-D-glucuronyl-13-S-dihydro-4'-epidoxorubicin. This study demonstrates that a 135 mg/m2 bolus infusion given on a 3-weekly schedule is an appropriate initial dose for further clinical studies.